Scientists at Cedars-Sinai Medical Center have developed a new way to identify which prostate cancer patients are likely to develop aggressive types of the disease even if their tumors at first appear to be lower risk. Read the article here.
New way to identify patients at risk for aggressive prostate cancer Read More »
Scientists at Swansea University say they have made a breakthrough which could revolutionise prostate cancer treatment. Researchers at the university’s School of Medicine have developed a way of shrinking cancer cells using a harmless strain of salmonella bacteria. Read the article here.
Salmonella could shrink prostate cancer cells Read More »
A revolutionary new DNA treatment technique involves having a simple DNA test of your tumour first. This then tells doctors precisely which drugs or therapies are most suited to you – rather than relying on the standard treatment. The genetic profiling of your tumour can also tell doctors which drugs you should avoid because they either won’t help you or are likely to give you worse side effects than others might suffer. Read the article.
Revolutionary new cancer treatment makes patients SIX TIMES more likely to survive Read More »
The discovery of new prostate cancer biomarkers has led to a number of tests that have begun to alter the diagnosis and management of the disease. Read the article.
Markers redefining prostate cancer care Read More »
March 2016 Awareness Night Genetically Predisposed: Who is at Increased Risk of Developing Prostate Cancer? Justin Lorentz, MSc, CGC Certified Genetic Counsellor, Male Oncology Research and Education (MORE) Lead, Dept of Radiation Oncology Sunnybrook Odette Cancer Centre Dr. Danny Vesprini, MD, MSc, FRCPC Assistant Professor, U. of Toronto Dept of Radiation Oncology Affiliate Scientist, Biological Sciences, Sunnybrook Research Institute, Sunnybrook Odette Cancer Centre CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 85:01 minutes
A new genomic test, Oncotype DX, gauges how lethal a tumor is by looking at the expression of 17 genes in the tumor. Read the article.
New Diagnostic Tools for Prostate Cancer Read More »
Dr. Eleftherios Diamandis, a researcher at Toronto’s Mount Sinai Hospital, would like a better alternative that could reduce unnecessary biopsies. Dr. Diamandis plans to spend the next two years developing a non-invasive test that can help determine when high PSA levels warrant concern. To do this, he will zero in on genetic mutations found in the semen of men with prostate cancer and use those biomarkers to screen other men for the disease. Read the article.
Semen-based test for diagnosing prostate cancer could reduce unnecessary biopsies Read More »
(TORONTO, Canada – Nov. 13, 2014) – Prostate cancer researchers have developed a genetic test to identify which men are at highest risk for their prostate cancer to come back after localized treatment with surgery or radiotherapy. Read the article.
Prostate cancer researchers develop personalized genetic test to predict recurrence risk Read More »
Go to the PCC website for the latest news, including New research to determine low-risk from high-risk prostate cancer and previous news items. You can also subscribe here to a monthly newsletter.
PCC News: New research to determine low-risk from high-risk prostate cancer Read More »
Patients with prostate cancer and hereditary mutations in the BRCA2 gene have a worse prognosis and lower survival rates than do the rest of the patients with the disease. This is the main conclusion to come out of a study published this week in the Journal of Clinical Oncology, in which David Olmos, Head of the Prostate Cancer and Genitourinary Tumours Clinical Research Unit at the Spanish National Cancer Research Centre (CNIO), has taken part in, along with Elena Castro, a member of the Unit, and British researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation
First genetic factor in prostate cancer prognosis identified Read More »